BioMedWire Stocks

Shining the Spotlight on Asthma During Pregnancy

Asthma is a respiratory condition that affects around 9.7% of adult women and 6.2% of adult males. Researchers believe the condition is more prevalent in girls and women as fluctuating levels of hormones, including progesterone and estrogen, can affect a woman’s airways.

For women with asthma, pregnancy comes with additional risks. Pregnancy by itself is a risky endeavor that often puts incredible mental and physical strain on expectant mothers.  With the presence of asthma, pregnant asthmatic women can find it extra hard to breathe during asthma attacks; such attacks can reduce the amount of oxygen going to the fetus and result in issues such as developmental delays and growth abnormalities.

Compared to healthy women, women with asthma are slightly more likely to develop high blood pressure during pregnancy. They also have a higher risk of preeclampsia, a high blood pressure disorder in pregnant women that is characterized by disruptions in the function of blood vessels in the placenta. Preeclampsia can lead to the development of general high blood pressure and cause damage to the brain, kidneys, liver and other organs in pregnant mothers.

Uncontrolled asthma in asthmatic pregnant women can result in abnormally slow fetus growth by limiting the oxygen supply to the baby as well as preterm births, lower-than-usual birth weights, and even death while still in-utero or after birth. Consequently, it is crucial that asthmatic women engage with their healthcare providers to develop asthma action plans before or when they get pregnant to help protect both the mother’s and baby’s health.

Such a plan would limit inflammation in the airways and reduce the number of asthma attacks the mother suffers while pregnant. The first move would be to connect an asthma doctor with an obstetrician and make sure they discuss how to handle treatment for the duration of pregnancy.

Pregnant women should also contact their doctor or seek emergency aid right away if they notice that the baby is moving less than usual during or after an asthma attack as even a few minutes of oxygen deprivation can cause fetal death. Regular ultrasounds will allow an obstetrician to monitor the fetus’ growth and will be especially helpful in checking a baby’s condition after a women experiences an asthma attack. Pregnant women will also want to avoid asthma triggers such as dust mites and tobacco to avoid triggering a new asthma attack.

If asthma attacks are caused by allergies, a physician may recommend treating the allergies to keep the asthma at bay during pregnancy.

Companies such as BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are seeking to develop better therapeutics against autoimmune conditions, including allergies, so that different groups of patients, such as pregnant women, can effectively manage those illnesses while enjoying a better quality of life.

NOTE TO INVESTORS: The latest news and updates relating to BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma

Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the…

12 hours ago

Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium

The company revealed the trial at the Australia Translational Breast Cancer Research Symposium (“ATBCR”) Sapu-003…

12 hours ago

How Rural Health Care is Being Impacted by the Federal Funding Landscape

Approximately 20% of people in the U.S. live in a rural area, and they face…

4 days ago

$37.5M Grant Announced to Boost Management of Infectious Diseases in the US

On October 15, NETEC (National Emerging Special Pathogens Training & Education Center) announced a grant…

5 days ago

What Patients Need to Know About the Remission Rate of Glioblastomas

Patients are overwhelmed when they are diagnosed with glioblastoma, the most deadly primary brain cancer.…

7 days ago

Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability

Thermostable vaccine technology is considered a significant unmet need in epidemic preparedness. Soligenix has been…

7 days ago